Drugs in Dev. Infections and Infectious Diseases
Preclinical
France 
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Chlamydia Vaccine Candidate Granted Fast Track Designation by the US FDA
Details : Sanofi's chlamydia vaccine candidate is an mRNA-based prophylactic vaccine designed to prevent infections caused by the bacterium Chlamydia trachomatis.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 26, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Translate Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Translate Bio, Sanofi Covid-19 Vaccine Candidate Produces Immune Response
Details : An experimental coronavirus vaccine developed by Translate Bio and Sanofi SA induced immune response in non-human studies, with trials in humans expected to start in November.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 25, 2020
Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Translate Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : K-NK-ID101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will study NK-cell biology in COVID-19 patients, the elimination of SARS-CoV-2 virus and virally infected cells by K-NK cells, and synergies between monoclonal antibodies, vaccines and K-NK cells.
Product Name : K-NK-ID101
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 17, 2020
Lead Product(s) : K-NK-ID101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : SpikImm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
SpikImm and SATT Conectus Sign a Agreement for Prophylactic Treatment Against the BK Virus
Details : Under the agreement, SpikImm gains worldwide exclusive licensing agreement for potent monoclonal antibodies targeting the BK virus.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
June 12, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : SpikImm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Unitaid
Deal Size : $6.0 million
Deal Type : Funding
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria
Details : The mdc-STM is an investigational three-month active injectable formulation of ivermectin using Medincell’s BEPO technology to fight malaria transmission.
Product Name : mdc-STM
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 04, 2024
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Unitaid
Deal Size : $6.0 million
Deal Type : Funding
Lead Product(s) : OVX836
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : $1.5 million
Deal Type : Funding
Details : The funding will support preclinical studies evaluating the breadth of protection and immune response induced by the company’s lead, broad-spectrum influenza vaccine candidate, OVX836 against pandemic influenza strains.
Product Name : OVX836
Product Type : Vaccine
Upfront Cash : Undisclosed
May 12, 2023
Lead Product(s) : OVX836
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : $1.5 million
Deal Type : Funding
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : The Medicines Patent Pool
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : This non-exclusive licence agreement, will enable MPP to support the identification of suitable partners for the development and commercialisation of mdc-STM, an injectable formulation of ivermectin with a three-month action-duration.
Product Name : mdc-STM
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 13, 2022
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : The Medicines Patent Pool
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : ANT3310,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Bpifrance
Deal Size : $10.0 million
Deal Type : Funding
Details : The funding for Antabio will allow to continue the development of ANT3310 towards clinical studies and reach crucial milestones such as the clinical demonstration of its safety and tolerability in humans.
Product Name : ANT3310
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 01, 2022
Lead Product(s) : ANT3310,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Bpifrance
Deal Size : $10.0 million
Deal Type : Funding
Lead Product(s) : COVID-19 Anti-CD40.COV2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : GTP Bioways
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The agreement with GTP relates to the development of Covid-19 Anti-CD40.COV2 vaccine, from development of the cell line to production of a clinical batch to be tested in a clinical trial. LinKinVax’s technology is based on a monoclonal antibody that ta...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 15, 2022
Lead Product(s) : COVID-19 Anti-CD40.COV2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : GTP Bioways
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : EB003
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The data presented at the CRISPR meeting continues to support the potential of our lead candidate EB003 and use of the Eligobiotics® platform to modulate bacterial populations of microbiome for treatment of severe diarrhea induced by shiga-toxin.
Product Name : EB003
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 15, 2021
Lead Product(s) : EB003
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
